ALDER BIOPHARMACEUTICALS INC Operating Cash Flow
ALDER BIOPHARMACEUTICALS INC reported Operating Cash Flow of -$133.87 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2019-08-06
- ALDER BIOPHARMACEUTICALS INC net cash provided by (used in) operating activities for the quarter ending 2019-06-30 was -$59.30M.
- ALDER BIOPHARMACEUTICALS INC net cash provided by (used in) operating activities for the quarter ending 2019-03-31 was -$74.58M.
- ALDER BIOPHARMACEUTICALS INC net cash provided by (used in) operating activities for the quarter ending 2018-12-31 was -$72.85M.
- ALDER BIOPHARMACEUTICALS INC net cash provided by (used in) operating activities for the quarter ending 2018-09-30 was -$51.47M.
- ALDER BIOPHARMACEUTICALS INC net cash provided by (used in) operating activities for fiscal 2018 was -$250.85M.
- ALDER BIOPHARMACEUTICALS INC net cash provided by (used in) operating activities for fiscal 2017 was -$226.62M.
- ALDER BIOPHARMACEUTICALS INC net cash provided by (used in) operating activities for fiscal 2016 was -$159.69M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$59.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$133.87M 10-Q · filed 2019-08-06 | -$206.72M derived: sum of 3 quarters · filed 2019-08-06 | -$258.20M derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | -$74.58M 10-Q · filed 2019-05-02 | -$147.43M derived: sum of 2 quarters · filed 2019-05-02 | -$198.90M derived: sum of 3 quarters · filed 2019-05-02 | -$251.33M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-12-31 | -$72.85M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | -$124.32M derived: sum of 2 quarters · filed 2019-02-25 | -$176.75M derived: sum of 3 quarters · filed 2019-08-06 | -$250.85M 10-K · filed 2019-02-25 |
| 2018-09-30 | -$51.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$103.91M derived: sum of 2 quarters · filed 2019-08-06 | -$178.00M 10-Q · filed 2018-11-05 | -$233.53M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-06-30 | -$52.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$126.53M 10-Q · filed 2019-08-06 | -$182.05M derived: sum of 3 quarters · filed 2019-08-06 | -$226.89M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | -$74.09M 10-Q · filed 2019-05-02 | -$129.62M derived: sum of 2 quarters · filed 2019-05-02 | -$174.46M derived: sum of 3 quarters · filed 2019-05-02 | |
| 2017-12-31 | -$55.53M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | -$100.36M derived: sum of 2 quarters · filed 2019-02-25 | -$226.62M 10-K · filed 2019-02-25 | |
| 2017-09-30 | -$44.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$171.09M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | -$126.25M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | -$159.69M 10-K · filed 2019-02-25 |